Apath LLC

CH Technologies is a partner to the scientific community, to create the innovative tools capable of supporting the advancement of inhalation toxicology research. We stand ready to offer complete solutions that harness our devotion to the sciences and our openness to re-engineering our product concepts to perfectly suit the needs of scientists working to expand the boundary of man's knowledge.

In the field of toxicology, whether inhalation, respiratory or test atmosphere generation for in-vivo and in-vitro research, the microscopic properties of particles (respirable or non-respirable), far exceed the power of our perception. Despite their small size, the impacts that they have on our lives and global environment are profound. Combining the latest technology with our established expertise in aerosol science, we work beyond the current capabilities of research to push the boundaries of particle, gas and vapor toxicology.

This is why here at CH Technologies, we believe the small things count. Our attention to detail has long been a mark of quality on our products, resulting not only in publications, but lasting relationships with our customers.

Wickenstones is a full service market access consultancy working with the pharmaceutical, biotech, diagnostic and device sectors.

Founded with two clear objectives:
- Build strong internal alignment for our clients to maximise the value of their assets.
- Overcome the complex and difficult challenges of market access through persistence and innovation.

Our project leaders have over 150 years experience in the healthcare industry and access consulting.

Backgrounds
General management in pharma - Market access leadership across European and global organisations - Medical affairs leadership and experience in top level market access consultancies.

Therapy Areas
Experience from phase I to beyond loss of exclusivity in many therapy areas including oncology – respiratory - mental health – cardiovascular – autoimmune – ophthalmology – vaccines – virology - dermatology & wound care.

Geographical Scope
We have global reach and experience including European markets - The USA – Brazil – Russia – India - China (BRIC) plus other Asian markets.

Reach
We have affiliated staff in the UK, Scandinavia, Italy, Spain, France and Switzerland.

Quality
All our work is underwritten by our commitment to quality.

ClinChoice is a full-service clinical CRO dedicated to offering high-quality, efficient and flexible solutions to pharmaceutical, biotechnology, medical device, and consumer products clients worldwide. With a 25 year history of success, ClinChoice continues to be The Standard of Excellence for biostatistics, clinical operations, data management, statistical programming, CDISC, regulatory affairs, medical affairs and pharmacovigilance. ClinChoice has established major delivery centers across US, China, Europe, India, Japan and the Philippines. It has over 1,800 employees globally, with a strong and talented team, and a growing clinical operations presence in seven countries across Asia, North America and Europe.

About us:
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that our customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, we balance knowledge of what works with a vision for what’s next, so we can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, our solutions enhance trial oversight, enable site optimization, increase patient engagement, and measure the efficacy of new clinical treatments while ensuring patient safety. In 2017, more than 60% of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs, and CROs have relied on ERT solutions in over 13,000 studies spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence.

Fountain Medical Development is a clinical contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services in China, US, Japan, and Europe. FMD has extensive global experience in multiple therapeutic areas. The company has completed dozens of registrations trials which supported marketing authorization applications in US and Europe.

Our people is the basis of our success. The 1,700+ professionals are dedicated and diverse. At any given moment, at least 3 languages are spoken in our 20 offices in Asia, US, and Europe.

FMD is on the forefront of the paradigm shift in global clinical development. The regulatory reform in China has the potential to fundamentally change how an innovative therapy is developed. FMD is on the frontline building and shaping the future.

FMD is large enough to serve 7 out the 10 largest Pharma companies, and nimble enough to customize to the needs of startup firms.

In the US and Europe, FMD is doing business as FMD K&L. In China, we operate under the name FMD. Whatever the names are, the company is managed globally by a seasoned senior management team comprised of industry veterans.

Together we build a bright future.